Sorrento Therapeutics Inc (SRNE)

[dia76ca]

I used to think of Sorrento as having 3 major categories...NON-OPIOID PAIN, COVID and IMMUNOTHERAPY.

1. NON-OPIOID PAIN has near term blockbuster potential in SEMDEXA for sciatica. This is followed by non-opioid drugs for back pain, fibromyalgia, cancer and arthritic pain.

2. COVID therapies includes COVI-MSC for ARDS and LongHaulers, COVI-SHIELD for injection and nasal drops and Mpro an oral broad spectrum anti-viral.

3.IMMUNOTHERAPY includes both Cancer and Inflammation. Abivertinib for many cancers, lupus, and MS, several PD-L1, many ADNAB(Mayo Clinic), DAR-Ts, ADCs and an oncolytic virus.

I now think we should acknowledge two more categories. LYMPHATIC DELIVERY and TESTS>

4.LYMPHATIC DELIVERY also includes both Cancer and Inflammation. In both cases SOFUSA delivers drugs to the lymphatic system in lower, safer and
more effective doses.

5. The TESTS portfolio is driven by exponentially increasing COVISTIX revenues. The acquisition of FORTUNE and VIREX can allow Sorrento to produce affordable, near PCR quality, rapid tests for many viruses and cancers.

ALL 5 CATEGORIES HAVE SEVERAL POTENTIAL BLOCKBUSTER PRODUCTS!